Drug Trial Radar · NCT03287232
Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)
Last checked: Nov 20, 2026Latest source record: Apr 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
653
Actual
Start
Oct 16, 2017
Primary completion
Mar 8, 2019
Study completion Jul 22, 2019
Sponsor
- Lead sponsor
- EndoCeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 19, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to confirm the efficacy of intravaginal prasterone (DHEA) on Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women.
Conditions
- Hypoactive Sexual Desire Disorder
Interventions
Placebo Vaginal InsertDrug
Daily administration of a placebo vaginal insert.
Prasterone 6.5 mg (0.50%) Vaginal InsertDrug
Daily administration of a 6.5 mg (0.50%) prasterone vaginal insert.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sexual desireTime frame: 28 weeks
- Distress from low sexual desireTime frame: 28 weeks
Locations
69 sites in 2 countries. Site status is shown where the registry gives one.
Endoceutics site # 106
Huntsville, Alabama
Endoceutics site # 104
Mobile, Alabama
Endoceutics site # 117
Tucson, Arizona
Endoceutics site # 108
Berkeley, California
Endoceutics site # 121
Los Alamitos, California
Endoceutics site #128
Los Angeles, California
Endoceutics site # 30
San Diego, California
Endoceutics site # 17
San Diego, California
Endoceutics site # 36
Denver, Colorado
Endoceutics site # 52
Denver, Colorado
Endoceutics site # 125
New London, Connecticut
Endoceutics site # 7
Washington D.C., District of Columbia
Endoceutics site # 95
Bradenton, Florida
Endoceutics site # 120
Coral Gables, Florida
Endoceutics site # 99
Fort Myers, Florida
Endoceutics site # 26
Jacksonville, Florida
Endoceutics site # 60
Lake Worth, Florida
Endoceutics site #118
Miami Lakes, Florida
Endoceutics site # 54
North Miami, Florida
Endoceutics site # 92
Oviedo, Florida
Endoceutics site # 105
Sanford, Florida
Endoceutics site # 114
St. Petersburg, Florida
Endoceutics site # 89
West Palm Beach, Florida
Endoceutics site # 80
West Palm Beach, Florida
Endoceutics site # 90
West Palm Beach, Florida
Endoceutics site # 107
Decatur, Georgia
Endoceutics site # 119
Roswell, Georgia
Endoceutics site # 23
Sandy Springs, Georgia
Endoceutics site # 91
Savannah, Georgia
Endoceutics site # 111
Wichita, Kansas
Endoceutics site # 55
Wichita, Kansas
Endoceutics site # 88
Lexington, Kentucky
Endoceutics site # 86
Louisville, Kentucky
Endoceutics site # 103
Boston, Massachusetts
Endoceutics site # 22
Kalamazoo, Michigan
Endoceutics site # 123
Portsmouth, New Hampshire
Endoceutics site # 101
Berlin, New Jersey
Endoceutics site # 50
Neptune City, New Jersey
Endoceutics site # 44
New Brunswick, New Jersey
Endoceutics site # 81
Plainsboro, New Jersey
Showing 40 of 69 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.